Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib

New biological therapies continue to emerge in breast cancer. Recent advances with anti-angiogenesis therapies and anti-HER2 therapies highlight the next generation of treatments that will be entering clinical practice. Important questions regarding these targeted treatments remain, however. There are uncertainties as to how best to integrate new drugs into existing treatment algorithms, whether to use monotherapy or combination therapy with chemotherapy, and how to manage novel side effects seen with these agents. This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual-kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. E-mail: hburstein@partners.org

References

  • 1.

    FolkmanJ. Tumor angiogenesis: therapeutic implications. N Engl J Med1971;285:11821186.

  • 2.

    RosenLS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist2005;10:382391.

  • 3.

    DvorakHFBrownLFDetmarMDvorakAM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol1995;146:10291039.

    • Search Google Scholar
    • Export Citation
  • 4.

    BrownLFBerseBJackmanRW. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol1995;26:8691.

    • Search Google Scholar
    • Export Citation
  • 5.

    GuidiAJFischerLHarrisJRSchnittSJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst1994;86:614619.

    • Search Google Scholar
    • Export Citation
  • 6.

    GuidiAJSchnittSJFischerL. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer1997;80:19451953.

    • Search Google Scholar
    • Export Citation
  • 7.

    WeidnerNFolkmanJPozzaF. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst1992;84:18751887.

    • Search Google Scholar
    • Export Citation
  • 8.

    WeidnerNSempleJPWelchWRFolkmanJ. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med1991;324:18.

    • Search Google Scholar
    • Export Citation
  • 9.

    LinderholmBKLindhBBeckmanL. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer2003;4:340347.

    • Search Google Scholar
    • Export Citation
  • 10.

    WillettCGBoucherYdi TomasoE. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med2004;10:145147.

    • Search Google Scholar
    • Export Citation
  • 11.

    HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 12.

    SandlerAGrayRBrahmerJ. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial—E4599 [abstract]. J Clin Oncol2005;23(Suppl 16):Abstract LBA4.

    • Search Google Scholar
    • Export Citation
  • 13.

    YangJCHaworthLSherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003;349:427434.

    • Search Google Scholar
    • Export Citation
  • 14.

    MillerKWangMGralowJ. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 7001.

    • Search Google Scholar
    • Export Citation
  • 15.

    CobleighMALangmuirVKSledgeGW. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol2003;30(suppl 16):117124.

    • Search Google Scholar
    • Export Citation
  • 16.

    BursteinHParkerLMSavoieJ. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat2002;76(suppl 1):S115.

    • Search Google Scholar
    • Export Citation
  • 17.

    RamaswamyBEliasADKelbickNT. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res2006;12:31243129.

    • Search Google Scholar
    • Export Citation
  • 18.

    BursteinHJSpigelDKindsvogelK. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat2005;94(supp 1):S6.

    • Search Google Scholar
    • Export Citation
  • 19.

    TrainaTARugoHCaravelliJ. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) [abstract]. J Clin Oncol2006;24(suppl 1): Abstract 3050.

    • Search Google Scholar
    • Export Citation
  • 20.

    PegramMYeonCKuN. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat2004;88(supp 1):S124125.

    • Search Google Scholar
    • Export Citation
  • 21.

    MillerKDChapLIHolmesFA. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol2005;23:792799.

    • Search Google Scholar
    • Export Citation
  • 22.

    MillerKDWangMGralowJ. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat2005;94:S6.

    • Search Google Scholar
    • Export Citation
  • 23.

    OvermoyerBSilvermanPLeemingR. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treat2004;88(suppl 1):S106.

    • Search Google Scholar
    • Export Citation
  • 24.

    WedamSBLowJAYangSX. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol2006;24:769777.

    • Search Google Scholar
    • Export Citation
  • 25.

    MotzerRJHutsonTETomczakP. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol2006;24(suppl 1): Abstract LBA3.

    • Search Google Scholar
    • Export Citation
  • 26.

    DemetriGDvan OosteromATBlacksteinM. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 4000.

    • Search Google Scholar
    • Export Citation
  • 27.

    EscudierBSzczylikCEisenT. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 4510.

    • Search Google Scholar
    • Export Citation
  • 28.

    MillerKDBursteinHJEliasAD. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC). Breast Cancer Res Treat2005;94:S61.

    • Search Google Scholar
    • Export Citation
  • 29.

    Moreno-AspitiaAHillmanDWWiesenfeldM. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane [abstract]. J Clin Oncol2006;24(suppl 1): Abstract 577.

    • Search Google Scholar
    • Export Citation
  • 30.

    TsudaHTakarabeTHasegawaT. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol1999;30:11341139.

    • Search Google Scholar
    • Export Citation
  • 31.

    CoussensLYang-FengTLLiaoYC. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science1985;230:11321139.

    • Search Google Scholar
    • Export Citation
  • 32.

    AkiyamaTSudoCOgawaraH. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science1986;232:16441646.

    • Search Google Scholar
    • Export Citation
  • 33.

    MullerWJSinnEPattengalePK. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell1988;54:105115.

    • Search Google Scholar
    • Export Citation
  • 34.

    VogelCLCobleighMATripathyD. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol2002;20:719726.

    • Search Google Scholar
    • Export Citation
  • 35.

    SlamonDJLeyland-JonesBShakS. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001;344:783792.

    • Search Google Scholar
    • Export Citation
  • 36.

    RomondEHPerezEABryantJ. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med2005;353:16731684.

    • Search Google Scholar
    • Export Citation
  • 37.

    JoensuuHKellokumpu-LehtinenPLBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006;354:809820.

    • Search Google Scholar
    • Export Citation
  • 38.

    Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005;353:16591672.

    • Search Google Scholar
    • Export Citation
  • 39.

    SlamonDJEiermannWRobertN. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim efficacy analysis. Presented at the 28th Annual San Antonio Breast Cancer Symposium. December 8–11 2005; San Antonio Texas.

    • Search Google Scholar
    • Export Citation
  • 40.

    RusnakDWLackeyKAffleckK. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther2001;1:8594.

    • Search Google Scholar
    • Export Citation
  • 41.

    XiaWMullinRJKeithBR. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene2002;21:62556263.

    • Search Google Scholar
    • Export Citation
  • 42.

    WoodERTruesdaleATMcDonaldOB. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res2004;64:66526659.

    • Search Google Scholar
    • Export Citation
  • 43.

    ZhouHKimYSPeletierA. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys2004;58:344352.

    • Search Google Scholar
    • Export Citation
  • 44.

    XiaWLiuLHHoP. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene2004;23:646653.

    • Search Google Scholar
    • Export Citation
  • 45.

    KonecnyGEPegramMDVenkatesanN. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res2006;66:16301639.

    • Search Google Scholar
    • Export Citation
  • 46.

    KimTEMurrenJR. Lapatinib ditosylate GlaxoSmithKline. Drugs2003;6:886893.

  • 47.

    BenceAKAndersonEBHalepotaMA. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs2005;23:3949.

    • Search Google Scholar
    • Export Citation
  • 48.

    VersolaMJBurrisHAIIIJonesS. Clinical activity of GW572016 in EGF10003 in patients with solid tumors [abstract]. J Clin Oncol2004;22(suppl 1): Abstract 3047.

    • Search Google Scholar
    • Export Citation
  • 49.

    BurrisHAIIIHurwitzHIDeesEC. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol2005;23:53055313.

    • Search Google Scholar
    • Export Citation
  • 50.

    BlackwellKKaplanEHFrancoSX. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract]. J Clin Oncol2004;22(suppl 1): Abstract 3006.

    • Search Google Scholar
    • Export Citation
  • 51.

    BlackwellKBursteinHJPegramM. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab-refractory metastatic breast cancer [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 3004.

    • Search Google Scholar
    • Export Citation
  • 52.

    GomezHLChavezMADovalDC. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH-positive advanced or metastatic breast cancer [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 3046.

    • Search Google Scholar
    • Export Citation
  • 53.

    SpectorNLBlackwellKHurleyJ. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response [abstract]. J Clin Oncol2006;24(suppl 1): Abstract 502.

    • Search Google Scholar
    • Export Citation
  • 54.

    NagataYLanKHZhouX. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell2004;6:117127.

    • Search Google Scholar
    • Export Citation
  • 55.

    GomezHLDovalDCChavezMA. Biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Presented at the 28th Annual San Antonio Breast Cancer Symposium; December 8–11 2005; San Antonio Texas. Abstract 1071.

    • Search Google Scholar
    • Export Citation
  • 56.

    LinNUCareyLALiuMC. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer [abstract]. J Clin Oncol2006;24(suppl 1): Abstract 503.

    • Search Google Scholar
    • Export Citation
  • 57.

    BendellJCDomchekSMBursteinHJ. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer2003;97:29722977.

    • Search Google Scholar
    • Export Citation
  • 58.

    LinNUBellonJRWinerEP. CNS metastases in breast cancer. J Clin Oncol2004;22:36083617.

  • 59.

    PestalozziBCBrignoliS. Trastuzumab in CSF. J Clin Oncol2000;18:23492351.

  • 60.

    KeefeDL. Trastuzumab-associated cardiotoxicity. Cancer2002;95:15921600.

  • 61.

    Tan-ChiuEYothersGRomondE. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol2005;23:78117819.

    • Search Google Scholar
    • Export Citation
  • 62.

    PerezEAByrneJAHAmmondIW. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib [abstract]. J Clin Oncol2006;24(suppl 1): Abstract 583.

    • Search Google Scholar
    • Export Citation
  • 63.

    GeyerCEForsterJLindquistD. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med2006;355:27332743.

  • 64.

    StemmlerHJKahlertSSiekieraW. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie2005;28:582586.

    • Search Google Scholar
    • Export Citation
  • 65.

    JonesSFHainsworthJDSpigelDR. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [abstract]. J Clin Oncol2004;22(suppl 1): Abstract 2083.

    • Search Google Scholar
    • Export Citation
  • 66.

    ChuQGoldsteinLMurrayN. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 3001.

    • Search Google Scholar
    • Export Citation
  • 67.

    StornioloAMBurrisHAIIIPegramM. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab: a clinically active regimen [abstract]. J Clin Oncol2005;23(suppl 1): Abstract 559.

    • Search Google Scholar
    • Export Citation
  • 68.

    ChuIBlackwellKChenS. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res2005;65:1825.

    • Search Google Scholar
    • Export Citation
  • 69.

    OsborneCKShouJMassarwehS. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res2005;11:865s870s.

    • Search Google Scholar
    • Export Citation
  • 70.

    EllisMJCoopASinghB. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol2001;19:38083816.

    • Search Google Scholar
    • Export Citation
  • 71.

    De LaurentiisMArpinoGMassarelliE. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res2005;11:47414748.

    • Search Google Scholar
    • Export Citation
  • 72.

    XiaWGerardCMLiuL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene2005;24:62136221.

    • Search Google Scholar
    • Export Citation
  • 73.

    CarlsonRWAndersonBOBursteinHJ. The NCCN Breast Cancer Guidelines version 12007. Available at:www.nccn.org.

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 65 65 19
PDF Downloads 17 17 2
EPUB Downloads 0 0 0